Avacopan

Active ingredient description

Avacopan is a selective antagonist of the human complement 5a receptor (C5aR1 or CD88) and competitively inhibits the interaction between C5aR1 and the anaphylatoxin C5a. The specific and selective blockade of C5aR1 by avacopan reduces the pro-inflammatory effects of C5a, which include neutrophil activation, migration, and adherence to sites of small blood vessel inflammation, vascular endothelial cell retraction and permeability.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L04AA59
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA59

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
TAVNEOS Hard capsule
Summary of Product Characteristics (SPC)

Medicines

Avacopan is the active ingredient of these drugs:

Drug
Countries
TAVNEOS

Estonia Ireland Japan Poland

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₃₃H₃₅F₄N₃O₂
Molecular mass: 581.656 g/mol

External identifiers

CAS Substance: 1346623-17-3
DrugBank Drug: DB15011
KEGG Drug: D11093
PubChem Compound: 49841217
RxNorm Ingredient: 2572100
UNII Identifier: O880NM097T
AVACOPAN
 
Next: Usage >